IperionX Limited IPX
IperionX remains a pre-revenue critical minerals developer with accelerating losses — operating income deteriorated from -$22.5M in FY2024 to -$39.3M in FY2025 (year ended 2025-06-30) — and free cash flow burn of -$39.4M against equity of $92.4M. A confirmed July 2026 cluster buy by five insiders (~$2.6M) and 24-month net insider buying of $88.6M signal conviction, while the proposed U.S. redomiciliation and 200-ton titanium run-rate target provide a credible commercialization narrative.
However, an August 2026 fraud investigation announcement, a stock price of $21.01 trading 39% below its 200-day MA of $34.37, and a negligible smart-money score of 0.005 keep this a binary execution story best held until revenue materializes.
What could go wrong
- Fraud investigation. A law firm announced a fraud investigation into IperionX on August 17, 2026, creating legal and reputational overhang that could pressure shares regardless of operational progress.
- Cash burn acceleration. Free cash flow burn worsened from -$26.7M in FY2024 to -$39.4M in FY2025, with capex rising to -$17.6M; at this rate the $92.4M equity base erodes within roughly two years absent new capital.
- Pre-revenue indefinitely. The company has generated zero revenue across all five reported fiscal years (2021–2025), and no specific revenue commencement date is confirmed.
- Technical breakdown. Stock at $21.01 as of 2026-08-28 sits below both the 50-day MA ($24.32) and 200-day MA ($34.37), with RSI at 42.2 and MACD in negative territory, indicating persistent downtrend.
What would change my mind
Where this comes from: FMP annual fundamentals, FY2025 and FY2024 · FMP annual fundamentals, FY2025 · FMP annual fundamentals, FY2025 · Insider transaction data, 2026-07-10 to 2026-07-14. Orin's read on IPX; not advice.
Twelve months actual closes to 2026-09-23 · actual filings
50-day average 200-day average · volume below
On file
All IPX filingsLargest holders · 13F Q2 2026
Money flow| Filer | Position | Of fund |
|---|---|---|
| Woodline Partners | $19.4M | 0.1% of fund |
| Millennium Management | $17.2M | 0.0% of fund |
| Tudor Investment Et Al | $2.4M | 0.0% of fund |
| Point72 Asset Management, L.P | $2.0M | 0.0% of fund |
| Morgan Stanley | $1.9M | 0.0% of fund |
| Bank Of America /De/ | $1.6M | 0.0% of fund |
15 filers · quarter ended Q2 2026 · positions, not flows
Insiders, last 24 months: 30 Form 4 filings, net $88.6M. Of the 30 on hand, 16 were open-market purchases and 0 sales— the rest are grants, option exercises and tax withholding.
Ask Orin about IPX
Orin answers questions about IPX from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.
Start 3 free days →Where it trades
| Metric | Now | Own median | Sector |
|---|---|---|---|
| P/B | 6.4× | — | — |
What Wall Street published
$43
$26 – $53 · +118% against today's price
- 3 buy or overweight
- 0 hold
- 0 underweight or sell
The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.
Against the companies it is compared to
| Company | Market cap | P/E | EV/EBITDA | Gross | Net | ROE |
|---|---|---|---|---|---|---|
| IPXIperionX Limited | $663M | — | — | 0.0% | 0.0% | -35% |
| HUNHuntsman Corporation | $2B | — | 13.3× | 13.5% | -2.9% | -6% |
| USARUSA Rare Earth Inc | $2B | — | — | -54.1% | -2159.3% | -23% |
The median is of the 2 peers listed above and nothing else — check it against the column. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.
What it has traded at
What its sector has traded at
Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.
Every estimate on one scale
The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.